Evaluating the Next Steps for Research in Myelofibrosis
Laura Michaelis, MD, discusses the next steps for research in the treatment of myelofibrosis following the addition of fedratinib to the armamentarium of JAK inhibitors.
Selecting Cytoreductive Therapy for Patients with PV or ET
Laura Michaelis, MD, discusses how to select patients with either polycythemia vera or essential thrombocythemia for cytoreductive therapy.
Understanding Thrombotic Risk in ET and PV
Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses thrombotic risk for patients with essential thrombocythemia and polycythemia vera.